SPOT-MAS stands for Screening for the Presence of Tumor by Methylation and Size. This test uses next-generation sequencing (NGS) to evaluate ctDNA in the blood and detect the five most common cancers – liver, breast, lung, colorectal and stomach in Southeast Asia.
SPOT-MAS has been clinically validated across 10,000 asymptomatic cohorts achieving a robust performance for Sensitivity, Specificity and Positive Predictive Value. The study showed a high positive predictive value (PPV) of 58.1% and tumor tissue of origin (TOO) prediction value of 84%*.